JGC
PTHS

J. Goldman & Co’s Pelthos Therapeutics PTHS Stock Holding History

J. Goldman & Co’s Portfolio PTHS Stock Details PTHS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.06M Sell
50,415
-27,591
-35% -$654K 0.03% 408
2025
Q4 		$2.42M Buy
+78,006
New +$2.25M 0.06% 293

Other funds holding PTHS

M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return
DMKJ
David M. Knott Jr $168M AUM 60.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PFCS
Pale Fire Capital SE Prague, Czech Republic $1.14B AUM 42.87% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

J. Goldman & Co's PTHS Position: Q1 2026 in Review

J. Goldman & Co reduced its Pelthos Therapeutics (PTHS) stake by 35% in Q1 2026, selling an estimated $654K and leaving 50,415 shares worth $1.06M. The position accounts for 0.03% of the portfolio, ranked #408.

J. Goldman & Co first reported a position in PTHS in Q4 2025 and has held it in 2 quarters since. The position peaked at $2.42M in Q4 2025. 17 funds tracked by Wall St. Rank hold PTHS as of Q1 2026.

  • J. Goldman & Co held 50,415 shares of Pelthos Therapeutics worth $1.06M as of Q1 2026.
  • J. Goldman & Co sold 27,591 Pelthos Therapeutics shares in Q1 2026, an estimated $654K.
  • Pelthos Therapeutics made up 0.03% of J. Goldman & Co's portfolio in Q1 2026, its #408 holding.
  • J. Goldman & Co first reported a position in Pelthos Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • J. Goldman & Co's Pelthos Therapeutics position peaked at $2.42M in Q4 2025.
  • 17 funds tracked by Wall St. Rank held Pelthos Therapeutics as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.